Opinion|Videos|April 9, 2025
Integrating New AD Therapies Into Clinical Practice
Author(s)Matthew Zirwas, M.D.
An expert discusses key considerations dermatologists should keep in mind when integrating newer therapies into their clinical practice, including implementing protocols for patient monitoring and promoting treatment adherence.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some key considerations dermatologists should keep in mind when integrating newer therapies into their clinical practice (e.g., implementing protocols for patient monitoring, promoting treatment adherence)?
Advertisement
Related to this article
A review of 57 studies found music eases pain through positive emotion, control and moving in time with the beat, according to recent research out of Drexel University.
UC San Diego researchers found that early-onset metabolic dysfunction-associated steatotic liver disease cirrhosis was linked to higher genetic risk and Type 2 diabetes prevalence.
Behavior-informed care applies behavioral science principles to personalize support, including positive reinforcement and timely prompts.
Elevated levels of immunoglobulin G (IgG) drive “inflammaging” processes that take a toll on skin tissue as people age, according to research results reported by Japanese researchers. Reducing IgG may mitigate the loss of collagen and elastin.
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
ProAct Chief Operating Offier Deborah Dempsey says plan sponsors still lack the data and visibility to know whether they were shorted on a 340B claim.
AACR Cancer Progress Report 2026 highlights a 35% U.S. cancer death decline, new FDA advances, persistent disparities, and urgent calls for stronger NIH/NCI funding.
Advertisement
Advertisement